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ABSTRACT 
A number of quinones have been shown to be efficient anticancer agents. However, some mechanisms of their 
action, in particular cell signaling are not well understood. The aim of this study was to partly fill this gap by 
characterizing the mode of cytotoxicity of 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone (MeDZQ) in malignant 
mouse hepatoma cells (MH-22A) with regard to the expression and activation of main molecules in MAPK cell 
signaling pathway. The study revealed unequal roles of MAP kinases in MeDZQ-induced cell death: the compound 
did not induce significant changes in ERK expression or its phosphorylation; JNK appeared to be responsible for 
cell survival, however, p38 kinase was shown to be involved in cell death. In order to assess the enzymatic activa-
tion mechanisms responsible for the action of MeDZQ, we have also found that the antioxidant N,N'-diphenyl-p-
phenylene diamine, the iron-chelating agent desferrioxamine, and DT-diaphorase inhibitor, dicoumarol, partly 
protected the cells from MeDZQ cytotoxicity. It points to parallel oxidative stress and bioreductive alkylation 
modes of the cytotoxicity of MeDZQ.  
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INTRODUCTION 
Quinones are among the most investi-
gated anticancer agents which have been stud-
ied for many years (Lown, 1983; Loadman et 
al., 2000). There are several modes of their 
action, among which the most important are: 
1) oxidative stress-type cytotoxicity arising 
from the ability of quinones to form free rad-
icals, which may further undergo redox cy-
cling in aerobic conditions (Cassagnes et al., 
2015) thus forming reactive oxygen species 
(ROS) which provoke quinone-induced apop-
totic (Ollinger and Kagedal, 2002; Park et al., 
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2011) and necrotic (Nemeikaite-Ceniene et 
al., 2005) cell death;  
2) quinone intercalation with DNA (Sugiura 
et al., 1990) and/or topoisomerase inhibition, 
which is mainly characteristic for anthracy-
clines (Chen and Eastmond, 1995); and  
3) bioreductive activation of aziridinyl-sub-
stituted quinones (Sarlauskas et al., 2015). In 
this case, their net two-electron reduction cat-
alyzed mainly by NAD(P)H: quinone oxi-
doreductase (NQO1, DT-diaphorase) leads to 
the formation of corresponding hydroqui-
nones that alkylate DNA more readily than 
the parent quinones (Begleiter and Blair, 
1984; Morgan et al., 1997; Bolton et al., 2002; 
Siegel et al., 2012; Sarlauskas et al., 2015).  
One of potential antitumor quinones is 
2,5-diaziridinyl-3,6-dimethyl-1,4-benzoqui-
none (MeDZQ) (Figure 1). Its redox proper-
ties, e.g., the single-electron reduction poten-
tial (E17, or the redox potential of qui-
none/semiquinone couple, -0.23 V), and reac-
tivity towards the main enzymes responsible 
for its single- and two-electron reduction, re-
spectively, NADPH:cytochrome P-450 re-
ductase and NQO1, are similar to those of its 
aziridinyl-unsubstituted analogue, tetrame-
thyl-1,4-benzoquinone (duroquinone, DQ, 
E17 = -0.26 V (Miliukiene et al., 2014)).  
 
 
Figure 1: Structure of 2,5-aziridinyl-3,6-dimethyl-
1,4-benzoquinone (MeDZQ). 
 
Previous studies have shown that the re-
duction of aziridinyl-substituted quinones can 
regulate the activation of mitogen-activated 
protein kinases (MAPK) (Seanor et al., 2003; 
Park et al., 2011). In mammals, there are three 
main subfamilies of MAPKs: extracellular 
signal-regulated kinases (ERKs), c-Jun N-ter-
minal kinases (JNKs) and p38 isoforms (p38-
MAPKs) (Wada and Penninger, 2004; Huang 
et al., 2010). It has been shown that ERKs are 
mostly important for cell survival (Wada and 
Penninger, 2004), whereas JNK and p38 ki-
nases respond to a variety of stress signals 
(ionizing radiation, oxidative stress, inflam-
matory cytokines) and are known as the 
stress-activated protein kinases (SAPKs). 
They are shown to be involved in cell death 
processes (Wada and Penninger, 2004; Huang 
et al., 2010). However, the role of DNA dam-
age in the activation of SAPKs is complex; it 
is known that the immediate cell response is 
due to receptor activation whereas the late re-
sponse involves DNA damage (Batista et al., 
2009). Therefore, the elucidation of the sig-
naling pathways involved in quinone-induced 
apoptotic cell death may be useful in under-
standing of the modes of action of chemother-
apeutical agents and their further develop-
ment. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
MeDZQ was a generous gift by Dr. Jonas 
Sarlauskas (Department of Xenobiotics Bio-
chemistry, Institute of Biochemistry, Life Sci-
ences Center, Vilnius University). It was syn-
thesized according to a previously published 
procedure (Cameron and Gilles, 1968; Winski 
et al., 1998). Fetal bovine serum (FBS) was 
obtained from Life Technologies (USA), pen-
icillin-streptomycin, trypsin and EDTA were 
purchased from Biological Industries (Israel). 
Dulbecco's modified Eagle medium 
(DMEM), acridine orange/ethidium bromide 
(AO/EB) mixture, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), 
dicumarol (DIC), N,N'-diphenyl-p-phe-
nylenediamine (DPPD), desferrioxamine 
(DESF), MAPK inhibitors PD098059, 
SP600125 and SB203580 were obtained from 
Sigma-Aldrich (USA). Stock solutions (20 
mM) of all the inhibitors were prepared in di-
methyl sulfoxide (DMSO). Anti-phospho-
p38, anti-ERK and anti-JNK antibodies were 
purchased from Cell Signaling Technology 
(USA). Monoclonal antibodies for p38, phos-
pho-ERK, and phospho-JNK detection were 
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obtained from BD Biosciences (USA). Sec-
ondary goat anti-mouse and goat anti-rabbit 
antibodies (both conjugated with horseradish 
peroxidase) were purchased from Abcam 
(UK). Low melting-point agarose (LMPA) 
was purchased from Carl Roth (Germany), 
and standard agarose - from Thermo Fisher 
Scientific (USA). 
 
Cell culture and treatments 
To investigate MeDZQ toxicity, we used 
malignant mouse hepatoma cell line (MH-
22A) (Shvemberger and Alexandrova, 2000). 
The cells were grown in DMEM supple-
mented with 10 % of FBS, penicillin 
(100 U/ml), and streptomycin (100 μg/ml). 
The cells were maintained at 37° C in a hu-
midified atmosphere with 5 % CO2, and pas-
saged twice a week by detaching the cells 
with a 0.25 % trypsin/EDTA solution. For cy-
totoxicity testing, MH-22A cells were seeded 
at a density of 3.0×105 cells/ml in 96-well flat 
bottom plates (Sigma-Aldrich, USA) 
(100 µl/well) 24 h before the start of the ex-
periment. After reaching 60–80 % conflu-
ency, the cells were treated with MeDZQ, dis-
solved in DMSO (factor of dilution 1:2000). 
Inhibitors (DIC (20 µM), DPPD (2 µM), 
DESF (300 µM), PD098059 (20 µM), 
SP600125 (20 µM) and SB203580 (20 µM)) 
were added to the culture 30 min prior to 
MeDZQ exposure. All inhibitors were pre-
pared in DMSO, the final concentration of 
DMSO in the cell growth medium never ex-
ceeded 0.1 %. A corresponding amount of 
DMSO was added to the culture medium as a 
second control (first control – intact cells). 
 
Cell viability analysis 
After 24 h incubation with different con-
centrations of MeDZQ, the cells were washed 
with phosphate-buffered saline and treated 
with MTT solution (final concentration, 0.2 
mg/ml) for 1 h at 37° C. MTT is reduced to 
purple formazan only in living cells. After-
wards, it was dissolved in ethyl alcohol (100 
µl) and the absorbance was measured at 570 
nm using a microplate spectrophotometer 
Varioskan Flash (Thermo Scientific). The ab-
sorbance corresponds to the fraction of viable 
cells in the sample. The results were ex-
pressed as relative viability, i.e. average of ra-
tio: treated cells/control (intact) cells. The 
concentration of MeDZQ that killed 50 % of 
the cells in the test culture was considered 
LC50. 
 
Study of cell death 
Cell death after MeDZQ exposure was as-
sessed using two methods. 
The first one was microscopic cell analy-
sis after staining with AO/EB mixture (Mer-
cille and Massie, 1994). In short, the cells 
were grown for 24 h at MeDZQ LC50, then 
collected and 20 µl of cell suspension were 
mixed with AO/EB (3 µl) and analyzed using 
a fluorescence microscope (Olympus IX51). 
In each sample, 3x100 cells were calculated 
to determine the numbers of viable, viable 
apoptotic, nonviable apoptotic, necrotic and 
chromatin–free cells. 
The second method used was flow cytom-
etry (Guava easyCyte 8HT, Millipore). After 
quinone treatment, 200 µl of cell suspension 
(100-500 cells/µl) was mixed with 2 µl 
(0.1 mg/ml) AO/EB, incubated for 5 min, and 
then flow cytometry assay was performed. 
 
Western blot analysis 
The effect of MeDZQ on MAP kinases 
expression and phosphorylation was evalu-
ated using Western blot. Cells were lysed with 
ice-cold buffer (10 mM Tris HCl pH 7.4, 
50 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.1 
% BSA, 1 % Triton X-100, 1 mM PMSF, 2 
mM Na3VO4, 20 µg/ml aprotinin, pH 7.2). In-
soluble materials were removed by centrifu-
gation at 14 000 rpm for 15 min at 0-4° C. The 
remaining supernatant was then mixed with 
equal parts of 4×SDS sample buffer. Protein 
amounts were estimated using Bradford pro-
tein assay. Subsequently, SDS-PAGE (10 % 
acrylamide gels) was performed, and sepa-
rated proteins were transferred onto PVDF 
membranes. The blots were blocked with 
blocking buffer, 3 % low fat milk in TBST (4 
mM Tris HCl, 1 mM Tris base saline, 0.1 % 
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Tween 20, 154 mM NaCl), for 30 min at room 
temperature. The membranes were washed by 
TBST (3 x 5 min), probed first with primary 
antibody in 5 % low fat milk in TBST for 24 
h at 4° C, and then with the secondary anti-
body in the same 5 % low fat milk in TBST 
for 1 h at room temperature. After the incuba-
tion, membranes were washed by TBST (3 × 
5 min). Proteins were visualized using an 
Amersham ECL system. 
 
Statistical analysis 
Statistical analysis was performed using 
the Student’s t-test (Excel 2013, Microsoft). 
Data is presented as a mean ± standard error 
of at least 3 independent experiments. Differ-
ences were considered statistically significant 
at p < 0.05. 
 
RESULTS AND DISCUSSION 
First, the LC50 of MeDZQ was assessed – 
it was 0.31 ± 0.1 µΜ after 24 h of exposure 
(Figure 2). This MeDZQ concentration was 
used in all subsequent experiments. 
 
 
 
Figure 2: Cell viability decrease depending on the 
concentration of MeDZQ after a 24 h exposure (n 
≥ 3); LC50 of MeDZQ was found to be 0.31 ± 
0.1 µΜ. 
 
Before investigating the mechanisms of 
activity, the mode of cell death induced by 
MeDZQ was determined. 
It was carried out using fluorescence mi-
croscopy and flow cytometry. There are stud-
ies reporting that quinones induce apoptotic 
cell death (Sun and Ross, 1996; Fourie et al., 
2002; Park et al., 2011). Our results con-
firmed this fact showing that MeDZQ at LC50 
induced apoptosis: AO/EB staining demon-
strated 17 % of nonviable apoptotic and 15 % 
viable apoptotic cells (Figure 3A). A similar 
tendency was observed in the flow cytometry 
analysis. The data in Figure 3B shows a large 
number (more than 30 %) of apoptotic cells 
appearing after MeDZQ treatment. 
One of the main mechanisms responsible 
for aziridinyl-benzoquinone-induced cell 
death is their two-electron reduction to corre-
sponding hydroquinones by NAD(P)H: qui-
none oxidoreductase (NQO1). The activity of 
NQO1 in MH-22A cells is 79.5 nmol cyto-
chrome c reduced × mg protein–1 × min–1 (Ne-
meikaite-Ceniene et al., 2015). In order to 
evaluate the role of NQO1 in MeDZQ-in-
duced cell death, we used DIC, a well-known 
NQO1 inhibitor (Scott et al., 2011) which 
competes with NAD(P)H for binding to the 
active center of the enzyme. The protective 
effect of DIC shows that NQO1 significantly 
contributes to MeDZQ-induced cytotoxicity 
(Figure 4A). 
In order to assess other causes of cell 
death, the role of oxidative stress was evalu-
ated. For this purpose, we examined the ef-
fects of antioxidant DPPD and Fe-ion chelator 
DESF, because both of them were shown to 
be efficient in other studies (Shimoni et al., 
1994; Nemeikaite-Ceniene et al., 2005). Our 
results confirmed that DPPD and DESF pro-
tected the cells against the effect of MeDZQ 
(Figure 4B). It means that oxidative stress is a 
parallel mechanism of MeDZQ cytotoxicity. 
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Figure 3: Cell viability analysis after 24 h of MeDZQ (0.31 µM) treatment (n ≥ 3): (A) – cells stained with 
AO/EB dye mixture (V – viable; VA – viable apoptotic; NA – non-viable apoptotic; N – necrotic; CF – 
chromatin–free); (B) – cell death analysis by flow cytometry (n ≥ 3); percentage points of viable, apop-
totic and necrotic cell distribution. 
 
 
Figure 4: MH-22A cell viability after the treatment with (A) - MeDZQ together with NQO1 inhibitor DIC 
and (B) - antioxidants: DPPD and DESF. The results were registered using MTT assay and are pre-
sented as the average of relative viability, calculated from at least 3 independent experiments, ± SD. 
*Statistically reliable values between the viability of control (C) and MeDZQ treated cells (p < 0.05). 
**Statistically significant differences between cells treated solely with MeDZQ and DIC+MeDZQ, 
DPPD+MeDZQ, DESF+MeDZQ (p < 0.05).  
 
 
Among the many signaling pathways that 
respond to stress, MAPK family members 
(ERK, JNK, p38) are crucial for the cell fate. 
Two of them, JNK and p38, are known as 
SAPKs. There is evidence that following qui-
none exposure, some SAPKs take part in 
apoptosis induction (Park et al, 2011).  
It is known that ERK signaling pathway is 
involved in proliferation, differentiation and 
survival, however, there is data showing that 
ERK may participate in the activation of 
apoptotic cell death (Cagnol and Chambard, 
2010). We assessed the role of ERK by using 
its indirect inhibitor PD098059 which acts on 
ERK by inhibiting MEK1/2 activity (Alessi et 
al., 1995). We have found that in our model 
of malignant MH-22A cells, the ERK inhibi-
tor did not affect cell viability in the presence 
of MeDZQ. The changes in ERK expression 
and activation were also not detected (Figure 
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5A, B). Apparently, in MeDZQ induced MH-
22A cell death, ERK is not relevant. 
In contrast, the inhibitor of JNK, 
SP600125, which directly inhibits signal 
transduction, thus disabling the activation of 
one of the main downstream targets in the nu-
cleus c-Jun (Bennett et al., 2001; Cargnello 
and Roux, 2011), potentiated the cytotoxicity 
of MeDZQ (Figure 6A). However, the total 
amount of JNK in MH-22A cells did not 
change during 1-24 h incubation with 
MeDZQ. In contrast, the amount of activated 
(phosphorylated) JNK increased up to 6 h ex-
posure to MeDZQ and then started to gradu-
ally decrease (Figure 6B). The effect shows 
the early role of this kinase which looks like 
antiapoptotic in this case. 
In terms of p38, its inhibitor SB203580 
partly protected cells from MeDZQ-induced 
cell death (Figure 7A). It suggests that p38 ki-
nase contributes to cell death in this case.  
According to our data, during the first 3 h 
after the exposure, total amount of p38 protein 
was comparable (Figure 7B). However, fol-
lowing the exposure to MeDZQ after 24 h, the 
amount of protein decreased significantly. 
The levels of phospho-p38 increased after 1 h 
of exposure, but decreased after 3 h and dis-
appeared after 24-hour exposure. Therefore, 
contrary to JNK, p38 showed proapoptotic ac-
tivity upon MeDZQ effect. This is contradic-
tory to literature findings that cells with a 
large amount of NQO1 do not influence 
aziridinyl-benzoquinone induced apoptotic 
cell death via p38 kinase (Park et al., 2011). 
 
 
Figure 5: (A) - the effect of ERK kinase inhibitor on MH-22A cell viability at 24 h after MeDZQ and 
MeDZQ+PD098059 exposure, the results were registered using MTT assay and are presented as the 
average of relative viability, calculated from at least 3 independent experiments, ± SD. * Statistically 
significant differences between the viability of control (C) and MeDZQ treated cells (p < 0.05). **Statis-
tically significant differences between the viability of cells treated solely with MeDZQ and 
MeDZQ+PD098059 (p < 0.05). (B) - representative immunoblot images showing the ERK1/2 and phos-
pho-ERK1/2 protein expression in MH-22A cells after MeDZQ exposure; β-actin was used as a loading 
control. The relative level of the ERK1/2 and phospho-ERK1/2 protein expression was normalized to β-
actin and was expressed as the ratio of ERK1/2 /β-actin and phospho-ERK1/2 /β-actin as indicated at 
the bottom of the image; *p < 0.05, (n ≥ 3). 
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Figure 6: (A) - the effect of JNK inhibitor on MH-22A cell viability at 24 h after MeDZQ and 
MeDZQ+SP600125 exposure; MTT test absorbance averages from at least 3 independent experiments 
± SD. *Statistically significant differences between the viability of control (C) and MeDZQ treated cells 
(p < 0.05). **Statistically significant differences between the viability of cells treated solely with MeDZQ 
and MeDZQ+SP600125 (p < 0.05). (B) - representative immunoblot images showing the JNK1/2 and 
phospho-JNK1/2 protein expression in MH-22A cells after MeDZQ exposure; β-actin was used as a 
loading control. The relative level of the JNK 1/2 and phospho-JNK1/2 protein expression was normal-
ized to β-actin and was expressed as the ratio of JNK1/2 /β-actin and phospho-JNK1/2 /β-actin as indi-
cated at the bottom of the image; *p < 0.05, (n ≥ 3). 
 
 
The results show that the LC50 for the 
aziridinyl-benzoquinone MeDZQ was 
0.31 ± 0.1 µM in MH-22A cell culture. 
MeDZQ at LC50 caused apoptotic cell death. 
NQO1 inhibitor DIC increased viability of 
MH-22A cells following the MeDZQ expo-
sure. The significant protective effect of DIC 
has demonstrated that NQO1 significantly 
contributes to MeDZQ-induced cytotoxicity. 
Furthermore, the antioxidants DPPD and 
DESF protected the cells against the action of 
MeDZQ, which showed the involvement of 
oxidative stress in the quinone-induced cell 
death. MAP kinase study revealed unequal 
role in MeDZQ-induced cell death: the test 
compound did not induce significant changes 
in ERK expression, nor in its phosphoryla-
tion; JNK signaling appeared responsible for 
cell survival, however, p38 kinase might be 
involved in cell death. 
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Figure 7: (A) - the effect of p38 kinase inhibitor on MH-22A cell viability at 24 h after MeDZQ and 
MeDZQ+SB203580 exposure; MTT test absorbance averages calculated from at least 3 independent 
experiments ± SD. *Statistically significant  differences between the viability of control  (C)  and MeDZQ 
treated cells (p < 0.05). **Statistically significant differences between the viability of cells treated solely 
with MeDZQ and MeDZQ+SB203580 (p < 0.05). (B) - representative immunoblot images showing the 
protein levels of p38 and phospho-p38 after the MH-22A cell exposure to MeDZQ; β-actin was used as 
a loading control. The relative level of the p38 and phospho-p38 protein expression was normalized to 
β-actin and was expressed as the ratio of p38/β-actin and phospho-p38/β-actin as indicated at the bot-
tom of the image; *p < 0.05, (n ≥ 3).  
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